中国Akeso公司的新肺癌药物表现优于Merck的Keyturda, 凸显了中国生物技术的增长。 Chinese firm Akeso's new lung cancer drug outperforms Merck's Keytruda, highlighting China's biotech growth.

中国一家生物技术公司Akeso开发了一种肺癌药物Ivonescimab,该药物在试验中超过了Merck销售量最好的药物Keytruda,在试验中控制肿瘤11.1个月,而不是5.8个月。 A Chinese biotech firm, Akeso, has developed a lung cancer drug, Ivonescimab, which outperformed Merck's best-selling drug, Keytruda, in trials by controlling tumors for 11.1 months compared to 5.8 months. 这一突破突显了中国日益增长的生物技术部门,与西方公司增加了许可证交易。 This breakthrough highlights China's growing biotech sector, with increased licensing deals with Western companies. 尽管取得了这一进展,对中国非专利药品质量的担忧依然存在,尽管监管者捍卫了非专利药品的安全。 Despite this advancement, concerns about the quality of Chinese generic drugs persist, though regulators defend their safety.